Robert Siliciano, an AIDS researcher at the Johns Hopkins University School of Medicine, said on Monday at the XIV International AIDS Conference in Barcelona that HIV/AIDS will "never" be cured by antiretroviral medications because of latent HIV reservoirs in the body that avoid the impact of the drugs.
Robert Siliciano, AIDS researcher at the Johns Hopkins University School of Medicine
"I think what we know now is that with antiretroviral drugs, although we can control the infection, we can never cure it." He did add that with improvements to existing anti-HIV medications and new drugs, it may be possible for HIV-positive people to have normal life expectancies despite the latent HIV reservoirs that may never be eliminated.
John Mellors of the University of Pittsburgh said during an IAS-WHO (International AIDS Society - World Health Organisation) satellite meeting on HIV drug resistance, which is one of the major topics of discussion at the conference: "Inexperienced physicians treating patients with HIV/AIDS pose a risk factor for the development of drug resistance."
He provided some key points which have been learned:
No antiretroviral drug is resistance-proof. HIV has evolved to escape selective pressure whether it be from drugs or the immune system
Incomplete suppression of HIV replication leads to drug resistance. This is often associated with incomplete adherence; multiple drug resistance is found in up to 30% of people on HAART after two years
Resistance can lead to disease progression and death unless the viral RNA is suppressed to below 50 copies/mL
Resistant viruses can spread, and can affect initial responses to therapy
Resistance is not inevitable. Careful choice of regimens can minimise or prevent resistance
The WHO will set up a global drug resistance surveillance network to keep track of drug resistance worldwide. The programme will monitor outcomes to determine what causes or exacerbates, and what prevents drug resistance.
读者回应
抢先发表第一个回应吧!
请先登入再使用此功能。